Atlas Trials

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

Clinical trial NCT02340117 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02340117
Sponsor
SynerGene Therapeutics, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Pancreatic Cancer
Start date
2015-01-01
Primary completion
2026-12-01
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.